Biotecnologie Farmaceutiche
2014-2015
!"#$%&'%#()#*+,&-+#.+/)'0&+"-#
#
)1##
!"#$%&'#(#)"%*+,-.,&%/0&1%*
*
2"*3-%2%'$,*,)("*4$/5%'0*
!
2+(%3+4#5#6),/1%#789:##
Biotecnologie Farmaceutiche
2014-2015
Corso di Laurea Magistrale (+2) in:
• Biotecnologie farmaceutiche
– Classe: LM-09
Biotecnologie Farmaceutiche
2014-2015
Presidente del CCS in Biotecnologie Farmaceutiche
Barbara Gatto
Direttore del Dipartimento di Scienze del Farmaco
Manlio Palumbo
Tutors
Massimo Rosso
Anna Fortuna
Rappresentanti degli studenti
Lorenzo Bonaguro
Nicola Vajente
___________________________________________________________________
http://www.unipd.it/biotecnologie-farmaceutiche
http://www.dsfarm.unipd.it/corsi/corsi-di-laurea-1/corso-di-laurea-magistrale-biotecnologie-farmaceutiche
https://it-it.facebook.com/BiotecnologieFarmaceuticheUnipd
Biotecnologie Farmaceutiche
2014-2015
Ordinamento attuale: Laurea Magistrale in
Biotecnologie Farmaceutiche (LM-9):
dall’A.A. 2008-2009
Laurea Specialistica in Biotecnologie Farmaceutiche (LS-9):
dall’A.A. 2004-2005
Laurea Vecchio Ordinamento in Biotecnologie - Indirizzo
Farmaceutico:
dall’A.A. 2000-2001
Biotecnologie Farmaceutiche
2014-2015
Outline
Perché
Cosa
Come
Biotecnologie Farmaceutiche
2014-2015
Perchè
Biotecnologie Farmaceutiche
2014-2015
Il segmento più rilevante del settore biotecnologico è quello
relativo alle biotecnologie applicate alla salute dell’uomo
(terapia, diagnostica e drug delivery), sia per la numerosità delle
imprese sia per il numero degli addetti e l’entità degli
investimenti in R&S, nonché i volumi di fatturato espressi.
… questo settore include:
• Terapeutici
• Tecnologie e servizi per la drug discovery
• Drug delivery
• Tissue engineering
• Diagnostica molecolare
Rapporto sulle biotecnologie in Italia - Report 2011,
by Assobiotec, Farmindustria, ICE, Ernst&Young
Biotecnologie Farmaceutiche
2014-2015
http://assobiotec.federchimica.it/
Biotecnologie Farmaceutiche
2014-2015
=&'(9"-%&6!
(*
@]Ydl`[Yj]Zagl][`fgdg_q`YkYlj]e]f\gmkaehY[lgfe]]laf_l`]f]]\kg^hYla]flk&Alfglgfdq]f[gehYkk]k!
e]\a[af]kl`YlYj]eYfm^Y[lmj]\mkaf_YZagl][`fgdg_a[Ydhjg[]kk$ZmlYdkg_]f]Yf\[]ddl`]jYha]k$!
Adk]llgj]\]d^YjeY[gZagl][`
Yf\lakkm]]f_af]]j]\hjg\m[lk&9dkgafAlYdqj]\Zagl][`akl`]kh]Yj`]Y\k]_e]flg^l`]]flaj]k][lgj$!
oal`egj]l`Yf*,([gehYfa]kYf\Yfaf[j]Ykaf_fmeZ]jg^hjgb][lkY\\j]kkaf_\aY_fgkakYf\l`]jYhq$
o`a[`Yj]Yae]\Ylghlaearaf_l`]]flaj]hYl`oYqg^[Yj]Zgl`^jgeY[dafa[YdYf\][gfgea[hgaflg^na]o&
!"#$%&'()
*%+&,"-"&.%$"-/01&-2&-3%&.%,&#/2-%43&5%4-2.6&,%-"/$5&20&789:&"0,&;<.%&#/2-%43&42=;"0/%5&IK-.+6&H(LMJ
F]ddËYeZalg\]dj]\Zagl][`adk]llgj]\]d^YjeY[gZagl][`
Ad^g[mk\]dhj]k]fl]JYhhgjlgkmdd]aehj]k][`]kag[[mhYfg
>%,&#/2-%43
?@)A&>%;2.-B
?@)'&>%;2.hj]\geafYfl]$afl]jeafa\afme]jgaehj]k] /1!$
\]a^YjeY[aZagl][`$[agaehj]k]\]d^YjeY[g]Ydlj]Zagl][`
!2-"$&#/2-%43
C<.%&#/2-%43
!2-"$&#/2-%43
C<.%&#/2-%43
^YllmjYlg 1(!$Y\\]llaJK
1(!]\afn]klae]fla
0.!&
\]d^YjeY[g$adk]_e]flghajad]nYfl]\]dj]\Zagl][`&
#$%&'()*+),*%-./0'1
2""
3"4
2"3
3"5
Adk]llgj]\]d^YjeY[gZagl][`[gklalmalg\Yim]dd]aehj]k][`] DY>a_mjY*&*\]na\]frY\]ddYjad]nYfrY\alYd]k]llgj]
6*7.8)7$(/*9'(
:);<;34)%0880*/
:)3<35!)%0880*/
:);<;;2)%0880*/
:)3<3=")%0880*/
YddÌafl]jfg\]dj]\Zagl][`&?mYj\Yf\gYddYlahgdg_aY\aYra]f\Y$
kngd_gfgYllanald]_Yl]Yhjg\glla^YjeY[]mla[a$\jm_\]dan]jq$
6*7.8)0/9'17%'/7)0/)>?@
:)3<!53)%0880*/
:)!;=)%0880*/
:)3<!42)%0880*/
:)!;;)%0880*/
d]aehj]k]\]d^YjeY[g[gfljaZmak[gfgafdYj_YhYjl]Yd^YllmjYlg
l][fgdg_a]]k]jnarah]j\jm_\ak[gn]jq]nY[[afa LYZ]ddY*&)!&
1*!$Y\\]llaafJK5<23=
/+!]afn]klae]fla /1!\]dk]llgj]
6*7.8)>?@)'%-8*A''1
5<!"5
3<"="
3<"3;
\]d^YjeY[gZagl][`&
Adj]klg\]dj]\Zagl][`[gehj]f\]$gdlj]Ya[gke]la[a$dÌYj]Y\]a
"<YlY`Yn]Z]]fj][laÕ]\lgeYc]kYehd][gehYjakgfhgkkaZd]&
\aY_fgkla[a$[gehgklY\Yaehj]k]aeh]_fYl]hjaf[ahYde]fl]
Ad[Yehagf]\aaehj]k]gh]jYflaf]ddgknadmhhg]n]f\alY
f]ddYhjg\mragf]\a\akhgkalanae]\a[g%\aY_fgkla[aafnaljg
AN<!$
L`]ÕjekY[lan]afZagl][`fgdg_qYhhda]\
Y[lanalqafl`]j]\Õ]d\&9kYdj]Y\q
N81"+-/2(LNK2(K"$"6-)(;"-K0/%&5/2(O./%(
%-(!.51)(!&1$%!(15-.)%(%-(>?@(-7(%!&(
!"#!$"#!%&'(")(%!&(*+&,"-./(0&1+2(3&(1+&(
%-()15&(1(7&3(<(3!"6!2(1/(3&$$(1/(9&")#(
BioInItaly - 2014,
\a^YjeY[aZagl][`egdlgjYhhj]k]flYlang\]dhYfgjYeY
l]kl]e]lg\aZYkYlakm<F9'JF9h]jdY\aY_fgka$dYhjg_fgka
by Assobiotec, Farmindustria, Ernst&Young
%-%1$().59&+(-7(9"-%&6!(6-5*1)"&/A(
oalf]kkaf_Yk`jafcaf_$o`a[`j]Ö][lk
%!&(&4*+&//"-)(-7(%!&(-.%/%1)'")#(+&/.$%/(
alYdaYfg\]dd]Zagl][fgdg_a]\]ddYkYdml]h]j[`adfme]jg\a
]dYhj]\aragf]\akh][aÕ[`]hYlgdg_a]&Afl]jeafa
9&/"'&/(+&*+&/&)%")#().5&+"61$$0(5-+&(
%!&(&4%+&5&$0(6!1$$&)#")#(&6-)-5"6(
%!1%(510(1+"/&(7+-5(%!&(7+."%7.$(/0)&+#0(
aehj]k][`]kag[[mhYfg\a^YjeY[aZagl][`jYhhj]k]flYmfY
\ahjg\glla'k]jnara$dÌYj]Y\]a\aY_fgkla[aka[YjYll]jarrYh]j2
%!1)(!1$7(-7(%!&(B%1$"1)(9"-%&6!(")'./%+02(
7+15&3-+8(%!1%(51)0(-7(-.+(5"6+-(1)'(
-7(&)%+&*+&)&.+"1$(/8"$$/2(7-+31+'P$--8")#(
imglYka_faÕ[YlanY\]ddÌafl]jgk]llgj]
/1!&Jakh]llgYdd]*+0
hjg\glla2kljme]fla$eYl]jaYda\a[gfljgddg$cal]j]Y_]flah]jdY
l`]qYdkgY[[gmfl^gjYka_faÕ[Yfl
/51$$(*.+&(9"-%&6!(6-5*1)"&/(1+&(6-*")#(
afn]kle]flkYf\k[a]flaÕ[]ph]jlak]$Ydkg
aehj]k]aeha]_Yl]f]dk]llgj]j]\Zagl][`$af^Ylla$)00aehj]k]
\aY_fgkla[Y
*+-*-+%"-)(-7(%!&(%-%1$(%.+)-,&+(1)'(%!&(
oal`$Yko]ddYkl`]\a^Õ[mdla]kl`]q
+&5")'(./(%!1%(%!&+&("/(5.6!(3&(61)('-(
"),&/%5&)%/(-7(%!&(&)%"+&(/&6%-+:(
6-)%").&(716")#(")(/-.+6")#(,&)%.+&(61*"%1$:(
( ")(-+'&+(%-(7.$$0(&4*$-"%(%!&("))-,1%"-)(
ka\]\a[YfgY\Yllanalaf]j]flaYa^YjeY[aZagl][`$e]flj]ad
k]jnara2\aY_fgkla[Yafnaljg$Y^Õllg\ahaYllY^gje]]l][fgdg_a]
*-%&)%"1$(-7(B%1$"1)(9"-%&6!)-$-#"&/:(
2014-2015
j]klYfl]*)kag[[mhY\a\aY_fgkla[a]'g[gke]la[a&
hjghja]lYja]h]jYllanal\aja[]j[Y&
Biotecnologie Farmaceutiche
C!&().59&+(-7(+&'(9"-%&6!(6-5*1)"&/("/(
;&0-)'(%!&"+(6-)%+"9.%"-)(")(%&+5/(-7(
/$"#!%$0($-3&+(6-5*1+&'(%-(DEFGH(%!&($-//(
"),&/%5&)%(1)'(+&,&).&/2(+&'(9"-%&6!(
L`]lglYdfmeZ]jg^ÕjekY[lan]afl`]
-7(&"#!%(6-5*1)"&/(I/"4(-7(3!"6!(3&+&(*.+&( [gehYfa]k`Yn]ka_faÕ[Yfldq_jgofl`]aj
j]\Zagl][`Õ]d\ak*,) LYZd],&)!$
LYZ]ddY*&)%;Yeha\aYhhda[Yragf]%k]llgj]\]d^YjeY[gZagl][`
>gfl]2]dYZgjYragfa=jfklQgmf_!
9"-%&6!(6-5*1)"&/J(!1/()-%(9&&)(-77/&%(90(
*+-'.6%(*"*&$")&(1)'(!1,&(*+-,"'&'(%!&(
QF@(-7(3!"6!("/(51'&(.*(-7(6-5*1)"&/(
%!&(7-.+()&3(&)%+"&/(1)'(%!&(716%(%!1%(-)&(
]flj]hj]f]mjaYdYf\ÕfYf[aYd[geemfalq
'&'"61%&'(&46$./",&$0(%-(!.51)(!&1$%!A(
;Yeha\aYhhda[Yragf]
<]k[jaragf]
-%!&+(6-5*1)0(!1/(&4*1)'&'("%/(9./")&//(
3"%!(1().59&+(-7(%+.&(/.66&//(/%-+"&/(<(
%!&(+&51")")#(FR@(6-)/"/%/(-7(5.$%"P6-+&(
!"
Hjg\glla^YjeY[]mla[a
!"#$%#&'(%)"*+,&)$)-.'/*0)1"'2'3456
>YjeY[agYdljaYhhjg[[al]jYh]mla[a$[ge]d]l]jYha]ZYkYl]km_]fag[]ddmd]$af[dmka2
Zagdg_a[a Zagdg_a[Ydk!2hjgl]af]ja[geZafYfla$Yfla[gjhaegfg[dgfYda$hjg\gllaZYkYlakmdd]l][fgdg_a]
\]_daY[a\afm[d]a[a
[gehgklaYZYkkgh]kgegd][gdYj] keYddegd][md]k!2^YjeY[aknadmhhYla$l]klYlagaf\ana\mYlae]\aYfl]e]lg\a[`]
\ak[j]]faf_Zagl][`
l]jYha]YnYfrYl]2^YjeY[aZagdg_a[aknadmhhYlaYlljYn]jkgdYl]jYhaY[]ddmdYj]kgeYla[Y$dYl]jYhaY_]fa[Y
gdÌaf_]_f]jaYlakkmlYd]$mladarrYlakghjYllmllgh]jadljYllYe]flg\aeYdYlla]_]f]la[`]]\]_]f]jYlan]&
NY[[afa
N]f_gfgmladarrYlah]jdYhj]n]fragf]]dYl]jYhaY&
KgfgnY[[afahjg\glla[gfZagl][fgdg_a] ÉnY[[afaja[geZafYflaÊ![`]h]je]llgfg\aakgdYj]ad_]f][`][g\aÕ[Y
dYhjgl]afY\]dea[jgj_Yfakegaf_jY\g\aklaegdYj]dYjakhgklYaeemfalYjaY&
<jm_\]dan]jq
L][fgdg_a]h]jn]a[gdYj]a^YjeY[aYmfkalgkh][aÕ[ge]\aYfl]gllaearrYragf]\]ddgjgYkkgjZae]flg]\]ddYdgjg
\akljaZmragf] eYl]jaYdaYnYfrYla$dahgkgea$Yfla[gjha$l]jYhaY[]ddmdYj]$][[&!&
Im]klg[Yehg\aYhhda[Yragf]n]\]dgknadmhhg\ahjg\glla[`][gfkaklgfgafkakl]ea\ajadYk[ag[`]kgeeafakljYfg
afeg\geajYlgad^YjeY[gkgdgafmfÌYj]Y\aja^]jae]flg\]d[gjhg h]j]k]ehagf]al]kkmla[Yf[]jgka!]h]jmfh]jag\g
\al]ehg[gfljgddYlg&
<jm_\ak[gn]jq
Kafl]ka$gllaearrYragf]][YjYll]jarrYragf]\a\jm_[Yf\a\Yl]$knadmhhg\akY__a$Yllanal\ak[j]]faf_]nYda\Yragf]
kma^YjeY[a&
KaljYllY\amf[Yehg\aYhhda[Yragf][`]hj]n]\]kghjYllmllgdYn]f\alY\ak]jnara2
l][fa[`]\an]jaÕ[Y\]ddY^mfragfYdall]jYh]mla[Y\afmgn]egd][gd]
l]klkmhaYllY^gje][]ddmdYjaaf_]_f]jarrYl]Y\`g[h]jk]_fYdYj]]n]flmYdaj]YragfaYhjg\glla[`aea[agZagdg_a[a
kmhhgjlg[ge];gfljY[lJ]k]Yj[`Gj_YfarYlagf ;JG!&
)*
JYhhgjlgkmdd]Zagl][fgdg_a]\]dk]llgj]^YjeY[]mla[gafAlYdaYÆ*()*
an experimental drug or standard of care.
Each arm will operate independently
and be powered to demonstrate overall
survival as the primary endpoint. Interim
progression-free survival would be used to
determine whether an experimental drug
progresses from phase 2 to 3.
eral study arms in a single, ongoing, clinical
trial. Another change is that testing patient
DNA with next-generation sequencing can
provide more diagnostic information than
can be achieved with one test. This is a bold
move away from testing each drug with its
own companion diagnostic.
accounted for only 7% of revenue generated
by the top ten treatments worldwide in 2001,
but made up 71% of that revenue in 2012.
Over a similar period, biotech product sales
more than quadrupled, financing of biotech
research increased tenfold, and the amount
invested in pharma-biotech research alliances
increased sixfold. In fact, all parameters in the
Tufts report point in the same direction: pharma
has dramatically shifted its R&D strategy from
an almost singular focus on small-molecule
Box 1 First two drugs celebrate I-SPY2 graduation
Table 1 The first five squamous cell lung cancer treatment arms chosen for the drugs in the early 1990s to a dominant
focus on biotech products today. Driving the
master
protocol
launch
While the Friends of Cancer Research prepare to launch the Lung Cancer Master Protocol,
transformation are biotech products’ novel
sponsors
of the landmark phase 2 I-SPY2
trial are celebrating the
graduation of its first
Company/location
Compound
Target
mechanisms of action and ability to command
two
candidates, AbbVie’s veliparib
andMEDI4736
Puma Biotechnology’s neratinib.
Veliparib
and
MedImmune/Gaithersburg,
Maryland
mAb targeting
programmed
cell death high
1 prices, combined with the declining
neratinib were the first two drugs to enter into the trial, suggesting
it can deliver on its
ligand
patent lives of small-molecule drugs, the report
promise
of efficiently identifying whichAzd4547
patients respond to which
drugs. Across
the receptor tyrosine
said. Biotechnology
Industry
Organization
AstraZeneca/London
Fibroblast
growth factor
Biologics
have
replaced small molecules as the
Atlantic, in December, the European Union’s Innovative Medicines
Initiative
spokesperson Tracy
Cooleyfocus
says her
organization
kinase
inhibitorunveiled a
dominant
of big
pharma’s pipeline, and a
agrees that the new
growth
of biotech
€53
($72.7)-million
adaptive
trial to test
Alzheimer’s disease drug
candidates.
analysis
fromhas
thebeen
Tufts Center for the Study
Amgen/Thousand
Oaks,
California
Rilotumumab
A mAb
directed against hepatocyte growth
driven
in
part
by
those
factors,
though
the
shift has quantified
“These trials are the wave of the future,” says Hope Rugo, a trial
investigator and
factor
of Drug Development (Boston)
“can be largely attributed to a natural evolution
oncologist
at the
University
San Francisco School of
Medicine.
2012, about 40% of
Genentech/S.
San
Franciscoof California
Pictilisib
Phosphoinositide-3
kinase inhibitor of the industry.”the phenomenon. InEmily
Waltz
all biotech products in clinical development
The I-SPY2 trial, which launched in 2010, tests multiple drugs, from multiple
Pfizer/New York
Palbociclib
A cyclin-dependent kinase (CDK)-4 and
were
being
developed
by
big
pharma, up from
companies, in newly diagnosed breast (pd-0332991)
cancer patients before they
undergo
surgery
(Nat.
CDK6 inhibitor
Biotecnologie Farmaceutiche
NEWS
2014-2015
IN brief
It’s official: biologics are
Biologics have replaced small molecules as the dominant focus of pharma’s darlings
big pharma’s pipeline
• In 2012, about 40% of all biotech products in clinical
Biotechnol.
28, 383–384, 2010). Investigators use up to ten biomarker signatures
mAb, monoclonal antibody.
15.2 % in 2000, according to Ron Evens,
adjunct professor at the University of the
to stratify patients. They also feed early efficacy data into an adaptive randomization
IN theiranPacific
words
development
were
being
developed
byThedepending
big
pharma,
up from
in Stockton, California, who conducted
of action
ofenrolls
a particular
core innovation
in the master protocol
algorithm
that
patientscompound.
into differentWithin
treatment arms
on how previous
the study
with Boston-based Tufts. And in an
“This is among the
even more
metric,
worststartling
applications
of biotech products
accounted
for only 7%
of will
revenue generated
biotechnology.
They
AbbVie’s
veliparib,
a
poly(ADP-ribose)
polymerase
inhibitor,
graduated
in
triple-negative
Each arm will operate independently trial. Another change is that testing patient
by the increase
top ten treatments
worldwide in 2001,
the use of toxic
(HER2 negative, hormone receptor negative) patients, a particularly nonresponsive
but made
up 71%
that revenue in 2012.
and be powered to demonstrate overall DNA with next-generation sequencing can
pesticides
in of
industrial
population. An estimated 62% of patients receiving veliparib had a pathologic complete
whilebiotech product sales
Over a agriculture
similar period,
survival as the primary endpoint. Interim provide more diagnostic information than
response—no detectable tumor at the time of surgery—compared with 26% of patients
providing
absolutely
no
more than
quadrupled,
financing
of biotech
progression-free
survival
would
be
used
to
can
be
achieved
with
one
test.
This
is
a
bold
receiving the standard of care, Rugo reported at the San Antonio Breast Cancer
benefit
to consumers.”
research
increased
tenfold, and the amount
determine
whether
an
experimental
drug
move
away
from
testing
each
drug
with
its
Andrew
Kimbrell,
Symposium in December 2013. The most common adverse events were hematologic.
invested in pharma-biotech research alliances
executive director
of the Center
for In
Food
Safety,
progresses
from aphase
2 to 3.
own companion
diagnostic.
Puma’s neratinib,
multi-tyrosine-kinase
inhibitor, graduated
in HER2 positive,
increased
sixfold.
fact,
all parameters in the
heavily criticizes the USDA’s recommendation
hormone receptor–negative patients. Investigators will present pathologic complete
Tufts report point in the same direction: pharma
to deregulate Dow AgroSciences Enlist corn and
has dramatically shifted its R&D strategy from
response and adverse event data at a medical conference later this year.
soybean, which combines resistance to three
an almost
singular focus
on small-molecule
Box 1 First
two drugs
celebrate
I-SPY2 graduation
QuantumLeap
Healthcare
Collaborative,
who are coordinating
the I-SPY2 trial, are
herbicides, among
them glyphosate
and 2,4,D.
drugs2014)
in the early 1990s to a dominant
talking with AbbVie and Puma about launching I-SPY3, an adaptive collaborative
(Reuters, 3 January
focus
on
biotech
products
today. Driving the
Whiletothe
Friends
of Cancer
Research
to launch
Lung
Cancer
Master Protocol,
follow-on
I-SPY2.
“I-SPY3
will hope
to be aprepare
nimble way
to movethe
these
agents
relatively
“We lock up our refrigerator. We lock up our
are biotech products’ novel
sponsors
the 3,”
landmark
phase
2 at
I-SPY2
trialtime
are these
celebrating
the graduation
quickly
into a of
phase
says Rugo,
“but
the same
agents might
go in to of its firstfreezer. We locktransformation
up the pantry.” Mark Greenberg
mechanisms of action and ability to command
company-sponsored
I-SPY2
is still and
testing
five Biotechnology’s
more monotherapyneratinib.
or combinations
two candidates,trials.”
AbbVie’s
veliparib
Puma
Veliparib and of Denver, a consultant to a hedge fund, whose
high prices,
combined
with the declining
a rare condition
that
treatments,
and
more
arms
added.
drugs
have
out of the trial
so deliver
far.
neratinib
were
the
firstcan
twobedrugs
toNo
enter
into
thedropped
trial, suggesting
it can
on its son has Prader-Willi,
patent lives
of small-molecule
drugs, the report
results in uncontrollable
hunger.
Zafgen of
Inpromise
Europe, of
theefficiently
biomarker-driven
Alzheimer’s
disease
trial
is
expected
to
enroll
about
identifying which patients respond to which drugs. Across the
said. Biotechnology
Industry
Cambridge, Massachusetts,
announced
some Organization
1,500
patients.
The
project
is
a
proof-of-concept
trial
that
shares
many
of
the
I-SPY2
Atlantic, in December, the European Union’s Innovative Medicines Initiative unveiled apositive phase 2a
results in this
indication
spokesperson
Tracy
Cooley says her organization
features. It is part of the EU’s Framework Programme 7 and applications are due April 8.
with its anti-obesity
drug
beloranib,
a METAP2
agrees
that
the growth
of biotech has been
€53 ($72.7)-million adaptive trial to test Alzheimer’s disease drug candidates.
Asher Mullard Ottawa, Ontario, Canada
inhibitor. (New driven
York Times,
14
January
in part by those2014)
factors, though the shift
“These trials are the wave of the future,” says Hope Rugo, a trial investigator and
“can be largely attributed to a natural evolution
oncologist at the University of California San Francisco School of Medicine.
of the industry.”
Emily Waltz
patients
fare; the
algorithm
enrolls
more patients to
into treatment
arms when
positive
each arm,
patients
would
be randomized
is that multiple
agents
will be tested in sev15.2 % in
2000
signals
emerge, and fewer
negative of
signals
an experimental
drugwhen
or standard
care.emerge.
eral study arms in a single, ongoing, clinical
• biotech products accounted for only 7% of revenue generated
by the top ten treatments worldwide in 2001, but made up 71%
of that revenue in 2012
• pharma has dramatically shifted its R&D strategy from an
almost singular focus on small-molecule drugs in the early
1990s to a dominant focus on biotech products today
The I-SPY2 trial, which launched in 2010, tests multiple drugs, from multiple
they undergo surgery (Nat.
Biotechnol. 28, 383–384, 2010). Investigators use up to ten biomarker signatures
to stratify patients. They also feed early efficacy data into an adaptive randomization
algorithm that enrolls patients into different treatment arms depending on how previous
patients fare; the algorithm enrolls more patients into treatment arms when positive
signals emerge, and fewer when negative signals emerge.
AbbVie’s veliparib, a poly(ADP-ribose) polymerase inhibitor, graduated in triple-negative
(HER2 negative, hormone receptor negative) patients, a particularly nonresponsive
population. An estimated 62% of patients receiving veliparib had a pathologic complete
response—no detectable tumor at the time of surgery—compared with 26% of patients
receiving the standard of care, Rugo reported at the San Antonio Breast Cancer
Symposium in December 2013. The most common adverse events were hematologic.
Puma’s neratinib, a multi-tyrosine-kinase inhibitor, graduated in HER2 positive,
hormone receptor–negative patients. Investigators will present pathologic complete
response and adverse event data at a medical conference later this year.
QuantumLeap Healthcare Collaborative, who are coordinating the I-SPY2 trial, are
talking with AbbVie and Puma about launching I-SPY3, an adaptive collaborative
follow-on to I-SPY2. “I-SPY3 will hope to be a nimble way to move these agents relatively
quickly into a phase 3,” says Rugo, “but at the same time these agents might go in to
company-sponsored trials.” I-SPY2 is still testing five more monotherapy or combinations
treatments, and more arms can be added. No drugs have dropped out of the trial so far.
In Europe, the biomarker-driven Alzheimer’s disease trial is expected to enroll about
1,500 patients. The project is a proof-of-concept trial that shares many of the I-SPY2
features. It is part of the EU’s Framework Programme 7 and applications are due April 8.
Asher Mullard Ottawa, Ontario, Canada
companies,
in newly diagnosed
cancer
patients before
NATURE
BIOTECHNOLOGY
VOLUME 32breast
NUMBER
2 FEBRUARY
2014
117
IN their words
“This is among the
worst applications of
biotechnology. They will
increase the use of toxic
pesticides in industrial
agriculture while
providing absolutely no
benefit to consumers.”
Andrew Kimbrell,
executive director of the Center for Food Safety,
heavily criticizes the USDA’s recommendation
to deregulate Dow AgroSciences Enlist corn and
soybean, which combines resistance to three
herbicides, among them glyphosate and 2,4,D.
(Reuters, 3 January 2014)
Biotecnologie Farmaceutiche
Cosa
NATURE BIOTECHNOLOGY VOLUME 32 NUMBER 2 FEBRUARY 2014
2014-2015
“We lock up our refrigerator. We lock up our
freezer. We lock up the pantry.” Mark Greenberg
of Denver, a consultant to a hedge fund, whose
son has Prader-Willi, a rare condition that
results in uncontrollable hunger. Zafgen of
Cambridge, Massachusetts, announced some
positive phase 2a results in this indication
with its anti-obesity drug beloranib, a METAP2
inhibitor. (New York Times, 14 January 2014)
117
Biotecnologie Farmaceutiche
2014-2015
Laurea Magistrale
afferente al Dipartimento di Scienze del Farmaco
e alla Scuola di Medicina e Chirurgia
Classe di Laurea:
LM-9
CFU: 120
2 ANNI
Laureato Magistrale in
Biotecnologie Farmaceutiche
Biotecnologie Farmaceutiche
2014-2015
Finalità BioFarm
La finalità del Corso di Laurea Magistrale in Biotecnologie Farmaceutiche è di formare laureati
magistrali con una conoscenza scientifica adeguata per un impiego nella ricerca farmaceutica
accademica e industriale.
L'organizzazione e le esigenze della ricerca farmaceutica sono notevolmente cambiate negli
ultimi anni, sia per la scoperta e sviluppo di farmaci tradizionali “a piccole molecole”, sia per lo
studio e sviluppo di biofarmaci, ovvero proteine ricombinanti ed anticorpi monoclonali di nuova
concezione.
Il ricercatore farmaceutico necessita non solo di un’approfondita conoscenza negli ambiti
farmaceutici e tecnologici tipici dei biofarmaci, ma anche di un’approfondita preparazione in
biologia molecolare, biochimica strutturale, ingegneria genetica e ingegneria proteica. Le figure
professionali che operano nel campo della ricerca e produzione farmaceutica devono anche
possedere, oltre a conoscenze biotecnologiche di base, anche le specifiche competenze
tecniche e normative dedicate ai problemi relativi a ricerca, sviluppo, controllo e consulenza dei
farmaci di nuova concezione.
Biotecnologie Farmaceutiche
2014-2015
Finalità BioFarm
Le aree di apprendimento peculiari del Corso di Laurea Magistrale che
garantiscono la specificità rispetto ad altri corsi della stessa classe sono descrivibili
come: “area biologica”, “area biofarmaceutica” e “area tecnologicoapplicativa”, cui appartengono insegnamenti appartenenti alle discipline
biotecnologiche comuni, alle discipline di base applicate alle biotecnologie e
alle discipline farmaceutiche.
La formazione impartita mediante gli insegnamenti e i laboratori didattici del
Corso di laurea è integrata da seminari e corsi brevi dedicati ad argomenti
specialistici e innovativi delle biotecnologie, e completata dallo svolgimento di
una tesi sperimentale in laboratori di ricerca presso l’Università di Padova o in
laboratori pubblici e/o privati in Italia o all’estero, tramite convenzioni o progetti
LLP/Erasmus.
Biotecnologie Farmaceutiche
2014-2015
Il laureato in Biotecnologie Farmaceutiche dovrà possedere…
…conoscenze e competenze nei settori red biotech:
• Terapeutici: sviluppo di farmaci e altri approcci terapeutici, come le terapie basate
su geni o cellule.
• Tecnologie e servizi per la “drug discovery”: sintesi, ottimizzazione e
caratterizzazione dei farmaci candidati, sviluppo di saggi e attività di screening e
validazione sui farmaci.
• Drug delivery: tecnologie per veicolare i farmaci ad un sito specifico mediante
ottimizzazione dell’assorbimento e distribuzione del farmaco (materiali avanzati,
liposomi, anticorpi, terapia cellulare, etc).
• Diagnostica molecolare: test e metodi basati sul DNA/RNA per la diagnosi,
prognosi e predisposizione ad una malattia, per l’analisi di meccanismi patogeni e
per test di paternità (non sono considerati i classici approcci immuno-diagnostici).
Biotecnologie Farmaceutiche
2014-2015
Come
Biotecnologie Farmaceutiche
2014-2015
Tesi sperimentale
•Sviluppo,
30 CFU dedicati allo svolgimento
della tesi sperimentale in:
analisi e meccanismo
d’azione dei farmaci
•Tecnologie
di drug discovery
•Formulazione
•Biologia
e drug delivery
molecolare e strutturale
•Dipartimenti
dell’Università di
Padova
•Proteomica
di ricerca pubblici e
privati in Italia e all’estero
•Immunochimica
•Laboratori
•Diagnostica
•Laboratori
di ricerca europei
tramite progetti Erasmus (70%)
Abilità acquisite (skills)
! Conoscenza e capacità di
comprensione applicata
! Autonomia di giudizio e
capacità critica
! Abilità comunicativa in
italiano e in inglese
! Capacità di lavorare in team
(capacità relazionali)
! Problem solving/problem
setting
! Creatività
! Iniziativa
Conoscenze e competenze
Studio
Biotecnologie Farmaceutiche
2014-2015
Manifesto BioFarm
PRIMO ANNO
1. Basi Razionali dell’Attività dei Farmaci
7
CFU
2. Biochimica Strutturale
6
CFU
3. Biologia Molecolare 2
6
CFU
4. Chimica Organica e Analisi Farmaceutica Avanzate
7
CFU
5. Ingegneria Proteica
6
CFU
6. Farmacologia Molecolare e Sperimentale
10
CFU
6
CFU
8. Farmaci Biotecnologici
7
CFU
9. Delivery e Formulazione di Farmaci Biotecnologici
11
CFU
10. Diagnostica Microbiologica e Immunochimica
10
CFU
11. Corsi a scelta autonoma
8
CFU
Attività “Altre”
6
CFU
Tesi sperimentale
30
CFU
7. Metodologie Biochimiche e Proteomica
SECONDO ANNO
Biotecnologie Farmaceutiche
2014-2015
Come:
1. Insegnamenti aggiornati con la letteratura più recente
2. Lezioni in inglese:
• insegnamenti curriculari in inglese
• seminari in inglese da parte di
docenti stranieri (TS Erasmus)
!"#$%#&'()"'$'(*+#%#$
&*"
'!"
&!"
%&"
$)"
$!#!($!##"
%!"
$!##($!#$"
$!"
$!#$($!#%"
#!"
!"
$!#!($!##"
$!##($!#$"
$!#$($!#%"
3. Modalità di esame con ricerche bibliografiche, journal club,
presentazioni degli studenti
4. Approccio critico alla scienza: non solo insegnare la teoria…
5. Attività culturali organizzate dagli studenti:
Biotecnologie Farmaceutiche
2014-2015
Biotecnologie Farmaceutiche
2014-2015
Biotecnologie Farmaceutiche
2014-2015
!"#$%&'()
2014
JOB: Job Opportunities for Biotech
Lorenzo Bonaguro
Nicola Vajente
Ilaria Gregorio
Massimo Rosso
Linda Zambolin
Serena Genovese
Anna Di Bona
Nicolò Rozzino
Alessandro Mantese
Marta De Guglielmi
laf_]Y[`
%"#%(3#1(
#'3"(85160129
afl`]
3"(=&&>,(
$401%:&1%(%4(
`ak;gmfljq&
K[a]f[]!
`]AlYdaYf
f_dan]gfklY_]l`jgm_`
fkhgjlaf_l`]hmZda[afl`]ogjd\
*&,)+2%(3#+*%#0%)+%,.*%*4/3#0&,)#+%
kg[aYde]\aYkm[`Yk>Y[]Zggc
o]_]lcfgod]\_]YZd]YZgmlgmj
gea[k&
k]]`goAlYdqoYkkm[``a_`dq
ja]khYjla[ahYlaf_afl`akÕjkl
,.*%+879*0%#$%&(,):),)*'%,.&,%
fljq$af[dm\af_akdYf\k Õjklg^
*%,6/*%#$%&(,):),)*'%,.&,%.&:*%
*0'*%/893)(%&+-%,.&,%.&:*%
%/&0,)()/&+,'%)+,*+,%,#%/0*/&0*%
^gddgo]\^gjk]n]f\Yqk$\ak[mkkagfkgfl`]nYjagmkk][lgjk
#$%9)#,*(.+#3#265%,.*&,0*%/*0$#07&+(*'5%&0,%*4.)9),)#+'5%
alaf]jYflk[a]flaÕ[dYZgjYlgja]k$l`]L]d]l`gfZagl][`o]]c$
#/*+%-&6'%#+%$&07'%&+-%0*'*&0(.%(*+,0*'%#$%,.*%CDE%&+-%
7&+65%7&+6%#,.*0%&(,):),)*'?%
9f\l`]j]Ìkfg\gmZll`Yll`]j]oYkkge]l`af_lg[Yhlmj]
l`]Yll]flagfYf\aeY_afYlagfg^Yfqgf]oal`Yfgh]fYf\
)+F8)0)+2%7)+-?
MfhghmdYjYkh][lkg^Zagl][`o]j]\]ZYl]\oal`k[`ggd
(.)3-0*+%,.0#82.%G3&6%H*()-*5%&%2&7*%$#07&,%-*')2+*-%
,#/%$0&7*%-)'(8'')#+'%&9#8,%)7/&(,'5%0)'A'5%(#+(*0+'%&+-%
Z]f]Õlkg^Y\nYf[]\j]k]Yj[`&L`]YaeoYklgk`go`go
9)#,*(.%(#++*(,'%,#%-&)36%3)$*%&+-%,#%.*3/%2&7*0'%&00):*%&,%
(#7/0#7)'*'%)+%(#7/3*4%,*(.+)(&3%'89I*(,'?%
af_kafj]k]Yj[`Yf\Yo]dd%
5%'#7*%&'/*(,'%#$%9)#,*(.%&0*%
65%&+-%,.)'%.&'%.*3-%9&(A%,.*%
galoYkka_faÕ[Yfll`]AlYdaYf
:*+,'?
Abmkl`Yn]lgl`YfcYf\[gf_jYlmdYl]Yddl`gk]o`glggchYjl
afl`akÕjkl]\alagfYf\lg]f[gmjY_]qgmYddlghj]hYj]^gj
l`]f]pl]\alagfo`a[`oaddlYc]hdY[]ËZ]lo]]fG[lgZ]j.%
&+-%"<5%<=">?
fJge]oYk^gddgo]\Zq]n]flk$
[`afe]\a[af]$Zagj]Õf]ja]k$
][gfgea[_jgol`&O]`Yn]
!"#$"%&'()*%%
+',-'#"-.(/'0'-"%(12-*3"4&*
!"#$%#&'(%)"*+,&)$)-.'/*0)1"'2'3456
Biotecnologie Farmaceutiche
2014-2015
!"
Tesi sperimentale
• Dipartimenti dell Università di Padova
• Centri interdipartimentali di
ricerca (CRIBI)
• Laboratori in Italia e all estero tramite convenzioni e progetti
Erasmus (Mobilità internazionale laureati 2009: 61%)
Biotecnologie Farmaceutiche
2014-2015
internazionalizzazione
oltre la metà degli studenti partecipa a programmi di mobilità internazionale (oltre
60% degli studenti totali) (dato fornito in data 24/10/2013 dal Servizio Erasmus del
Dipartimento):
.4#:;9<=0>#?@A#B0#1/2BCB;D#5678198#
#E=8FC98/#5678198#GC7F=1=0;H#
"#:;9<=0>#?@A#B0#1/2BCB;D#5678198#-I4I4#
#E=8FC98/#5678198#GC7F=1=0;H#
$!!"#
,!"#
+!"#
*!"#
'!"#
(#
(#
./0#1/2#
(!"#
'!"#
&!"#
%!"#
%!$$-%!$%#
%!$!-%!$$#
,#
)!"#
)'"#
),"#
%!!,-%!$!#
3/24#5678198#
$$#
,#
)#
$!"#
!"#
%!!,-%!$!#
%!$!-%!$$#
%!$$-%!$%#
Rapporto di Riesame 2014
Biotecnologie Farmaceutiche
2014-2015
UNIVERSIDAD
DE JAÉN
www.pasteur-international.org
www.ujaen.es
www.epfl.ch
ERASMUS
PROJECTS
www.unizh.ch
www.ethz.ch
www.uni-bonn.de
www.unil.ch
www.uni-jena.de
Biotecnologie Farmaceutiche
2014-2015
Le abilità acquisite, ovvero conoscenza e capacità di comprensione applicata,
autonomia di giudizio, capacità critica e abilità comunicativa sia in italiano che in
inglese, permetteranno al laureato magistrale di possedere la preparazione
professionale per l'impiego in laboratori di ricerca dedicati:
•
alla ricerca, progettazione, sviluppo, formulazione ed analisi di farmaci innovativi e
biotecnologici;
•
alla ricerca e sviluppo nel campo delle tecnologie “omiche” (genomiche,
proteomiche e bioinformatiche);
•
alla gestione e controllo di qualità in ambito biomedici, diagnostico e nutrizionale;
•
alla collaborazione con organizzazioni pubbliche o private dedite alla
regolamentazione e documentazione nel settore biotecnologico-farmaceutico.
Il corso di Laurea Magistrale inoltre fornisce la preparazione adeguata per l'accesso a
Dottorati di Ricerca e Master Universitari di II livello in Italia e all’estero.
Biotecnologie Farmaceutiche
2014-2015
!
Figura 1: Indagine sull'opinione degli studenti BTF 2012/2013.
1: Azione Didattica; 2: Soddisfazione Complessiva; 3: Aspetti Organizzativi
Rapporto di Riesame 2014
Biotecnologie Farmaceutiche
2014-2015
Ammissione a BioFarm
•
Posti disponibili: 60
•
a. Preimmatricolazione via web: CONTROLLARE GLI AVVISI DI AMMISSIONE
su Uniweb
–
•
b. Test d ingresso: Per essere ammessi è necessario superare una prova di
ammissione, che consiste nello svolgimento di un tema su argomenti
riguardanti aspetti generali delle biotecnologie e che permetterà alla
Commissione esaminatrice di valutare l’adeguatezza della preparazione.
–
•
Quando? Luglio 2014
Quando? 23 Settembre 2014 (CONTROLLARE GLI AVVISI)
c. Immatricolazione in Segreteria come specificato negli AVVISI DI
AMMISSIONE
–
Quando? Ottobre 2014
Biotecnologie Farmaceutiche
2014-2015
Ammissione a BioFarm
a. Preimmatricolazione
Requisiti curriculari per l ammissione a Biotecnologie Farmaceutiche:
1. laurea nelle classi L-2, L-13, L-27, L-SNT30 (270) o nelle classi 1, 12, 21, SNT3
(509)
2. laurea in classi diverse da quelle al punto 1. per tutti quei laureati (anche
magistrali a ciclo unico) che abbiano ottenuto 100 CFU in esami dei Settori
Scientifici CHIM, FIS, MAT, BIO, MED come dettagliato nel Regolamento
Didattico.
NB: presentare la domanda alle Segreterie Studenti con l elenco degli esami
sostenuti
Biotecnologie Farmaceutiche
2014-2015
Ammissione a BioFarm
b. Test d ingresso
Per essere ammessi è necessario superare una prova di
ammissione, che consiste nello svolgimento di un tema su
argomenti riguardanti aspetti generali delle biotecnologie e
che permetterà alla Commissione esaminatrice e al
candidato di valutare l’adeguatezza della preparazione e a
predisporre attività di sostegno durante il primo semestre del
primo anno.
Biotecnologie Farmaceutiche
2014-2015
"!#$%$&!
Sono stati analizzati i Dati da Alma Laurea (laureati 2012):
il 79% degli studenti si dichiara soddisfatto del Corso di Studi completato; nell’anno
precedente era stato calcolato il 75%.
L’86% dei neolaureati contro l’81% dell’anno precedente si riscriverebbe allo stesso
Corso di Studi frequentato, mentre il 14% frequenterebbe un altro Corso di Studi dello stesso
Ateneo; nessuno si iscriverebbe allo stesso corso in un Ateneo diverso.
Per quanto riguarda l’ingresso nel mondo del lavoro su un campione di 14 intervistati
ad un anno dal conseguimento della laurea l’86% dichiara di avere un’occupazione che per il
43% riguarda la formazione post-laurea (dottorati di ricerca, borse, stage). A tre anni dalla
laurea su 12 intervistati risulta che il 100% ha un’occupazione, di questi il 56% svolge attività di
formazione post-laurea e tutti dichiarano di utilizzare le competenze acquisite con la laurea.
Rispetto ai dati dell’intero Ateneo, emerge che la soddisfazione dei laureati per
quanto riguarda l’organizzazione e la formazione prodotta dal corso di laurea, nonché l’utilizzo
in ambito lavorativo delle competenze acquisite è decisamente superiore alla media.
Rapporto di Riesame 2014
Biotecnologie Farmaceutiche
2014-2015
Sbocchi Professionali BTF
!"#$%&'&()
Le abilità acquisite, ovvero conoscenza e capacità di comprensione applicata,
autonomia di giudizio, capacità critica e abilità comunicativa sia in italiano che in
inglese, permetteranno al laureato magistrale di possedere la preparazione
professionale per l'impiego in laboratori di ricerca dedicati:
•
alla ricerca, progettazione, sviluppo, formulazione ed analisi di farmaci innovativi e
biotecnologici;
• !"#$%&'()*
alla ricerca e sviluppo nel campo
delle tecnologie “omiche”
!"#$%&'()=
!"#$%&'()@ (genomiche,
+,&-"."'/0%'1"20,."3,04'"2/%0.0'5"36078
/>&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3
+,&-"."'/0%'1"20,."3,04'"2/%0.0'/$%0'5"36078
+,&-"."'/0%'3%"#",04'"2/%0.0'5"36078
/>&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3
/>&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3
proteomiche e bioinformatiche);
?;
<(;
<(;
•
alla gestione e controllo di qualità in ambito >;biomedici, diagnostico e nutrizionale;
•
alla collaborazione con organizzazioni pubbliche o private<9;
dedite alla
<:;
:>;
9:;
regolamentazione
e documentazione nel settore(9;
biotecnologico-farmaceutico.
?;
*(;
=;
Il corso di Laurea Magistrale inoltre fornisce la preparazione adeguata
per l'accesso a
((;
Dottorati di Ricerca e Master Universitari di II livello in Italia e all’estero.
Q(E,"-45(
Q(F54$"(
Q(G$88&'"(
Q(F$8,&
DÌYfYdakah]jgja_af][gf^]jeY[ge]dY
*"++$&,"-."(/0123(45''5($*#,565(,"-%$(
$-("*7$%&(7$&%589(-"68"(8&*5(6%",%:;#<(
ad*+[ge]khaf%g^^Y[[Y\]ea[g$ad)-
[ge]ÕdaYd]\aemdlafYragfYd]$ad/[ge]
khaf%g^^gkhaf%gmlaf\mkljaYd]$ad,(
\Y^YjeY[]mla[YalYdaYfY$][ge]ad)*
"77$"(&,$+$-5(4$=5,6"(/>$+;,"()?@3?
Sbocchi Professionali BTF
Q(E,"-45(
Q(F54$"(
Q(G$88&'"(
Q(F$8,&
(:;
Q(H%",%:;#(
QKhaf%g^^Y[[Y\]ea[g
QKhaf%g^^gkhaf%gmlaf\mkljaYd]
Q(>",*"85;%$8"($%"'$"-"
Q(>$'$"'5(4$(*;'%$-".$&-"'5
Q(I'%,&
B*$'$"(W&*"+-"(/0U3(5(X5-5%&(/)T3<(
*5-%,5($'(-;*5,&(4$($*#,565(;7$8"%5((
-5''5(,5+$&-$(*5,$4$&-"'$(Q("-8&,"('$*$%"%&(
2014-2015
/>$+;,"()?13?
;gfja^]jae]flgYddYdgjg\akljaZmragf]
_]g_jYÕ[Y$d]aehj]k]Zagl][`\]d
8"*#$&-5(6&-&(#,5="'5-%5*5-%5(
8&-85-%,"%5(-5'(-&,4(5(-5'(85-%,&(O%"'$"?((
P"(P&*7",4$"(Q(&,*"$(6%&,$8"*5-%5('"(
,5+$&-5(8&-($'(#$R("'%&(-;*5,&(4$($*#,565(
7$&%589(/M)S3<(65+;$%"(4"(G$5*&-%5(/TU3<(
V&68"-"(5(P".$&(/0@(&+-;-"3<((
Biotecnologie Farmaceutiche
Y;"-%&("''"('&,&('&8"'$..".$&-5<($'(0U2((
45''5($*#,565(7$&%589(9"(6545(";%&-&*"<(
$'(TS2(Q('&8"'$.."%&("''Z$-%5,-&(4$(#",89$(
!"#$%&'()>
9fYdakah]jdg[YdarrYragf]_]g_jYÔ[Y$aehj]k]Zagl][`/>&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3
Q(J(KL
Q(MM(:(KL
Q(K(:(ML
Q(N(K
#$%&'()*'
+*,%$-.,
/$01'-'
#'2*$
3%*4*'56$%'7-'5
8,-,.$
9'(),7-'
:(*;4*58,-,2*'5<*;4*'
+;74*'
='%>'-*'5
#*7;(*'
9*1*4*'5
?'(1@,
/(,-.*-$5A4.$5A)*7,
='4'&(*'5
A&(;22$5
B%&(*'
8'44,5)CA$0.'5
?$4*0,
D'0*4*1'.'
<(*
?=
:@
:@
:=
(?
((
(A
>
>
@
=
=
?
:
:
(
<
<
<
A'
(A'
!"##$%&$'()**+',-$&+./$*$0-+'-/'1&"*-"'2'3456
?A'
*A'
@A'
<AA'
<(A'
<?A
!"
9$-&
#,5+$2=
C1$$/&
#,5+$2=
D=,+$&
#,5+$2=
9$-&
#,5+$2=
C1$$/&
#,5+$2=
D=,+$&
#,5+$2=
9$-&
#,5+$2=
#$%&''()*+,-#./
!
0
1
!2
0
0
1!
45678795:5)*;,/
0
1
1
0
1
0
0
;585$%75
1
0
1
1
0
0
11
0
;5=>5?75)*+,/
<
1
1
@
0
0
1!
($
1A
@
<
!"3
@
3
1E!
"
10
11
!
!2
A
0
2
@
1
1
!@A
1
0
1
0
0
E0
@@
E!1
!2 !<
1
1
"
0 0
0
0
11
($
""E 0
"
1A2
"1
"
2
0
0
2
2
0
2A
1
0
2<
0
0
!
!
0
20!
1
0
!
(
!
0
0
(
@
@
<<
JJK
EIH
J(HLJ
Biotecnologie Farmaceutiche
B=7875)C(=5D?5)*+,#.-;,/
!"#$%%"&'()
.%7&87),F?F'75)G7&875)
*"+,&-,&.,/+$.,&0$1&,&01,/2,0"%,&2"30,&-,&"00%,2"4,5/$6&.7--,8,.,5/$&0$1&9$:,5/$&!"#$%&'(&)*+#,*-.#$.(/,$0%(1(2#3$45
*+,/
Sbocchi Professionali BTF
9$:,5/,;
<73$15&-,&,301$.$&#,5+$2=;;
>301$.$&#,5+$2=?&&
@"++71"+5;;;
H5'7()*+,/
>301$.$&#,5+$2=?&&
!<
,/8$.+,3$/+,&,/&9AB;;;
C1$$/&
#,5+$2=
D=,+$&
#,5+$2=
9$-&
#,5+$2=
C1$$/&
#,5+$2=
#$%&''()*+,-#./
!
0
1
!2
0
45678795:5)*;,/
0
1
1
0
1
0 K5%9LF
;585$%75
1
0
1
1
0
0 K(876F)*#./
11
;5=>5?75)*+,/
0
($-
!
0
! !<
1
0
1
!
0
3
A@
1
1
@
0
0 M7F=(?:F)*+,-;,/
1!
($-
!"
0
@
<
!"3
@
3 M&D875)*+,-#.-;,/
1E!
"
1
($-
.%7&87),F?F'75)G7&875)
*+,/
10
11
!
!2
A
0
+5%JFD?5)*+,-;,/
2
@
H(=$5%J75)
;,/
*+,-#.-
!<
!
<
1I"!A
1
2
0
2
E0
0
1
3@
!3
1@
2I22@
E0
K5%9LF
"
!
!
!2
1
K(876F)*#./
1
1
0
0
0
M7F=(?:F)*+,-;,/
!"
3
11
""E
"
1
N%F?:7?()#8:()#J7DF
0
0
N(695?5)*+,/
@@
E!1
O=$%75)*;,/
1
"
,588F)JP#(6:5
0
11
,F?F:()*+,-;,/
1A2
"1
!5+"%$
0
0
0
"
<
H7D&%75)*+,/
1@
0
1A
+797875)*+,-#./
1
!@A
2 C1$$/&
#,5+$2=
($-
B=7875)C(=5D?5)*+,#.-;,/
H5'7()*+,/
>301$.$&#,5+$2=?&&
<
1I"!A
"--$++,&9AB
!
H7D&%75)*+,/
D=,+$&
9$-&
C1$$/& 2 D=,+$& 0 9$-&
#,5+$2=
#,5+$2=
#,5+$2=
#,5+$2=
#,5+$2=
H(=$5%J75) *+,-#.3@
!3
0 ;,/
1!
0
0
23
9$-&
#,5+$2=
EE
11
<
1
!2
($1
1
1<
1
1
($"
!
1
2
12
E'F
E2
1I!!2
A0
!I1AA
10
1
<
E
GF
1"
0
"@E
0
!1
1
E2
"
1E!
"
12
1
!
HE
"
"<
0 !"
!@
110
1
@
2"
1<
3!3
1@1
0
13
0
0
1A<
1@2
H(IHH
1
1
<
1
0
2
11
@
!
!@
2
+797875)*+,-#./
<
1
!
110
1
" [gfaf\a[Yragf]\]a[dmkl]j%KN K[a]fr]\]ddYNalY!%;N ;`aea[YN]j\]!%9> 9_jg%^gg\!Ç[mag_faJ]_agf]hYjl][ahY
0
2A
2
($"@
!@
1
"" [gehj]k]d]aehj]k]emdla%[gj]
!!!"#$"%#&#'$#"(#")
0
2<
($0
1!<
2
!2
N%F?:7?()#8:()#J7DF
1
1
1
1
0
0
!
N(695?5)*+,/
!2
2
<
3!3
!
0
O=$%75)*;,/
1
1
0
0
1
0
,588F)JP#(6:5
0
1
1
0
!
12
E
!
1A<
E'F
GF
HE
H(IHH
1
0
A
20!
!
0
<03
!
($-
0
11
0
0
($-
($-
0
@
@
<<
E
0
23<
JJK
EIH
J(HLJ
JJE
EL
F()'H
" [gfaf\a[Yragf]\]a[dmkl]j%KN K[a]fr]\]ddYNalY!%;N ;`aea[YN]j\]!%9> 9_jg%^gg\!Ç[mag_faJ]_agf]hYjl][ahY
"" [gehj]k]d]aehj]k]emdla%[gj]
!"
!!!"#$"%#&#'$#"(#")
6,*(73&0%.8(*)93$.(0#$#(0%*%.(%,*(.(:,#;#%#,.(
<&))*(9#0%.%3-.#$&(<&)(=)30%&,(6&9$#)#4.9#(
>*-.#$*)&(?9.&$-&(<&))*(@.%*(ABC?/CD
B*(6*+&))*(EDE(&F.<&$-.*(.(:,.$9.:*).(<*%.(<.(
0.$%&0.(<&)(0&%%#,&(+.#%&9G(:&,(#4$.(,&4.#$&(
alYdaYfY$af^mfragf]\]ak]_m]flahYjYe]lja2
fme]jg\aaehj]k]$^YllmjYlg$afn]klae]fla
.$(H1?8($3;&,#(<.(*<<&%%.(.$(H1?D
!E
2I22@
0
+5%JFD?5)*+,-;,/
!5+"%$
0
!
E0D=,+$&
#,5+$2=
M&D875)*+,-#.-;,/
,F?F:()*+,-;,/
2
@
1
0
11 1@
1 !1
($-
0
0
< "20
1
2014-2015
6,*(73&0%.8(*)93$.(0#$#(0%*%.(%,*(.(:,#;#%#,.(
E
1!
<&))*(9#0%.%3-.#$&(<&)(=)30%&,(6&9$#)#4.9#(
10
A
>*-.#$*)&(?9.&$-&(<&))*(@.%*(ABC?/CD
B*(6*+&))*(EDE(&F.<&$-.*(.(:,.$9.:*).(<*%.(<.(
<
0
0.$%&0.(<&)(0&%%#,&(+.#%&9G(:&,(#4$.(,&4.#$&(
!
0
alYdaYfY$af^mfragf]\]ak]_m]flahYjYe]lja2
"0
12
fme]jg\aaehj]k]$^YllmjYlg$afn]klae]fla
.$(H1?8($3;&,#(<.(*<<&%%.(.$(H1?D
ILG
FKF
!"##$%&$'()**+',-$&+./$*$0-+'-/'1&"*-"'2'3456
>&))*(6*+&))*(EDJ8(4).(0%&00.(<*%.(0#$#(
km\\anaka[gfja^]jae]flgYalj](
:,.$9.:*).(0&%%#,.(<.(*::).9*-.#$&(!,&<(
+.#%&9G8(4,&&$(+.#%&9G(&(KG.%&(+.#%&9G5(
$&.(73*).(#:&,*$#()&(.;:,&0&(.%*).*$&L(
*++.*;#(.$#)%,&(.$<.9*%#(.$(73*)&(<&.(%,&(
9)30%&,(0#:,*9.%*%.()&(0.$4#)&(H&4.#$.((
0#$#(9#.$F#)%&D
Biotecnologie Farmaceutiche
!"
C1$
#,5+
2014-2015
!"##$%&$'()**+',-$&+./$*$0-+'-/'1&"*-"'2'3456
Rapporto sulle biotecnologie del settore farmaceutico in Italia - 2012,
by Assobiotec, Farmindustria, Ernst&Young
0
($
E
1
2
(
1
!
E
JJ
Biotecnologie Farmaceutiche
2014-2015
Docenti
Antonella Caputo [email protected]
Barbara Gatto [email protected]
!"#$%&'(&")*"*'+*"#$%&,-&")*"*./"012,0)3'
Barbara Spolaore [email protected]
!")&"$%%*'4*1/)&'+*")&"$%%*,5*1/)&./"012,0)3'
6*78*7*'9*))&'+8*78*7*,#*))&./"012,0)3'
Chiara Bolego [email protected]
6*78*7*':1&%*&7$'+8*78*7*,;1&%*&7$./"012,0)3'''
Dorianna Sandonà [email protected]
4<0*7*'6&%$#&'+5<0*7*,8&%$#&./"012,0)3'
=&70*""*':*"2&">'+2&70*""*,;*"2&"*./"012,0)3'
Gianfranco Pasut [email protected]
90*"-7*"5&'?*;/)'+#0*"-7*"5&,1*;/)./"012,0)3'
Lisa90&7#0*'@0&%&'+#0&7#0*,A0&%&./"012,0)3'''
Dalla Via [email protected]
@&"05*'@&")&1&%0'+A&"05*,A&")&1&%0./"012,0)3'
Monica Montopoli [email protected]
?*)70B0*'?&%C$70"&'=$'D*/7$)&'+1*)70B0*,1&%C$70"&2$%*/7$)&./"012,0)3'
Patrizia Polverino De Laureto [email protected]
?*&%&':570A0"'+1*&%&,;570A0",/"012,0)3'
:)$-*"&':*%A*;&'+;)$-*"&,;*%A*;&./"012,0)3'
Marcella Bonchio [email protected]
:/;*""*'@*"27/BB*)&'+;/;*""*,A*"27/BB*)&./"012,0)3'''
Stefano Salmaso [email protected]
Susanna Mandruzzato [email protected]
Rappresentanti degli studenti
Tutors
Lorenzo Bonaguro: [email protected]
Anna Fortuna: [email protected]
Nicola Vajente: [email protected]
Massimo Rosso: [email protected]
© Copyright 2024 ExpyDoc
